Transcatheter thrombolysis combined with damage control surgery for treatment of acute mesenteric venous thrombosis associated with bowel necrosis: a retrospective study by unknown
RESEARCH ARTICLE Open Access
Transcatheter thrombolysis combined with
damage control surgery for treatment of
acute mesenteric venous thrombosis
associated with bowel necrosis:
a retrospective study
Kai Liu1, Jiaxiang Meng1, Shuofei Yang1, Baochen Liu1, Weiwei Ding2, Xingjiang Wu2* and Jieshou Li2
Abstract
Objective: This study aims to evaluate the clinical outcomes of transcatheter thrombolysis in acute superior
mesenteric venous thrombosis (ASMVT) associated with bowel necrosis.
Methods: A retrospective study of six patients with ASMVT treated with catheter-directed thrombectomy/thrombolysis
and damage control surgery at Jinling Hospital (Nanjing, China) between 2010 and 2013 was conducted. Demographics,
past medical history, risk factors, therapeutic methods and effects, mortality, and follow-up of the study
population were assessed.
Results: Five of six patients underwent arteriovenous combined thrombolysis, while one patient underwent
arterial thrombolysis. All patients required damage control surgery, and four of these patients underwent
temporary abdominal closure. All patients survived and were free of recurrence.
Conclusions: Transcatheter thrombectomy/thrombolysis and damage control surgery could help avoid extensive
bowel resection, prevent short bowel syndrome and reduce mortality for critically ill patients with acute mesenteric
venous thrombosis associated with bowel necrosis.
Keywords: Acute superior mesenteric venous thrombosis, Interventional thrombolysis, Damage control surgery, Bowel
necrosis
Introduction
Acute superior mesenteric venous thrombosis (ASMVT)
is an uncommon disease that presents no obvious spe-
cific symptoms in the early stage [1]. The diagnosis of
ASMVT remains elusive until intestinal gangrene and
peritonitis occurs [2]. The optimal time for treatment is
lost, and eventually massive bowel resection is required,
leading to short bowel syndrome [3–5]. Therefore, early
diagnosis and prompt therapy is very important to im-
prove the survival rate of patients with ASMVT, with
the goal of conserving as much bowel as possible [6–8].
For patients with ASMVT associated with bowel ische-
mia, the recommended treatment is emergency surgery.
However, in venous thrombosis, unlike arterial throm-
bosis, the line of demarcation is indistinct; leading to
massive bowel resection. This is associated with the de-
velopment of short bowel syndrome and high mortality
rates [1, 9]. In order to improve the viability of the ische-
mic and congested bowel secondary to mesenteric ven-
ous thrombosis, a strategy of initial transcatheter
thrombolysis followed by surgery has been adopted with
success [10, 11].
In this study, we evaluated the outcome of this novel
approach in critically ill patients combined with damage
control surgery.
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Materials and methods
All procedures performed in studies involving human
participants were in accordance with the ethical stan-
dards of the Ethics Committee of Jinling Hospital and with
the 1964 Helsinki declaration and its later amendments
or comparable ethical standards. Informed consent was
obtained from all individual participants included in the
study. Additional informed consent was obtained from
all individual participants for whom identifying informa-
tion is included in this article.
Patient group
This is a retrospective study of patients with ASMVT
treated between October 2010 and November 2013. Pa-
tients with ASMVT associated with bowel ischemia
treated with transcatheter thrombolysis followed by
damage control surgery were included in this study. Pa-
tient data were retrieved from medical records.
Diagnosis and evaluation
All patients underwent routine blood examination, in-
cluding: white blood cell, red blood cell, platelet and
neutrophilic granulocyte count; hemoglobin, C-reactive
protein, serum lactate and procalcitonin levels; and hep-
atic and renal function including amylase, lipase, amino-
transferase, urea, creatinine and phosphocreatine kinase
levels. Coagulation was monitored via thrombin time,
activated partial thromboplastin time, international nor-
malized ratio, fibrinogen, antithrombin III level, D-dimer
and thromboelastogram every 24 h throughout the
hospitalization. All patients underwent laboratory testing
for thrombophilic states.
All patients underwent Doppler ultrasound scans and
multislice spiral computed tomography (MSCT) to con-
firm ASMVT.
Initial management
Each patient was treated with emergent treatment in the
ICU to maintain hemodynamic stability. Vesical pressure
was regularly monitored to observe intra-abdominal pres-
sure changes. The use of vasopressors and somatostatin
were avoided, because these could exacerbate intestinal is-
chemia. Systemic anticoagulation for superior mesenteric
venous (SMV) thrombosis was carried out by immediate
subcutaneous low molecular weight heparin injection. Dex-
tran and alprostadil were used to improve microcirculation.
Thrombolytic technique
Before catheter-directed thrombolytic therapy, the risk of
bleeding complications and benefits of catheter-directed
thrombectomy and thrombolysis for acute SMV throm-
bosis were explained to each patient, and informed written
consent was obtained. Thrombolytic therapy was used for
patients with persistent or worsening abdominal pain des-
pite systemic anticoagulation.
Contraindications to percutaneous thrombolysis included
previous stroke, central nervous system malignancies, ac-
tive bleeding diathesis, and recent gastrointestinal bleeding.
Direct portal vein (PV)-SMV thrombolysis was not per-
formed in patients with unfavorable anatomy of the PV,
marked atrophy of the liver, or portal venous cavernous
transformation.
The route, thrombolytic agent, catheter type, length of
treatment, other interventional techniques, and compli-
cations are shown in Table 1.
Direct PV-SMV catheterization
The choice between direct-catheter thrombolysis by per-
cutaneous transhepatic or transjugular intrahepatic routes
was determined by radiologists and the gastrointestinal
surgeon based on the patient’s CT findings, vessel status
and general condition.
The portal vein was punctured under ultrasonography
and fluoroscopic guidance. After the injection of local
anesthesia, catheterization of the right hepatic vein was
performed using a 10-Fr, 41-cm long sheath (Rösch-Uchida
TIPS Puncture Set; Cook, Bloomington, IN, USA) via the
right transjugular approach. The catheter was advanced
further to puncture the right portal vein. Once the portal
puncture was successfully performed, an ultra-smooth
guide wire (Terumo Europe, Leuven, Belgium) was intro-
duced into the PV-SMV system. The SMV thrombus was
traversed using a 5-Fr Cobra catheter (Cordis, Miami,
USA). The thrombus in the PV-SMV system was aspirated
as much as possible using an angled 8-Fr guiding catheter
(Cordis, Miami, USA) with a 60-ml syringe through the 10-
Fr sheath. After most of the thrombi in the PV-SMV were
removed, a 5-Fr multiple side-hole catheter (Cordis, Miami,
USA) was securely placed within the SMV thrombus.
Alternatively, the right portal vein was punctured dir-
ectly with a 14-gauge trocar needle (Cook, USA) via the
right midaxillary line under ultrasonography guidance.
Then, a 6-Fr sheath (Cordis, Miami, USA) was intro-
duced into the PV-SMV system. The rest of the proced-
ure was the same as the prior TIPS method. After
thrombolytic treatment, the punctured tract was sealed
using a steel ring (Cook, USA) in order to prevent sub-
capsular hemorrhage.
SMA Catheterization
The right femoral artery was cannulated using the Seldinger
technique and a 5-Fr sheath (Cordis, Miami, USA) was
placed. A 5-Fr Cobra catheter (Cordis, Miami, USA) was
introduced; then, superior mesenteric arteriography and in-
direct portal and mesenteric vein venography were per-
formed. Subsequently, selective catheterization of the
superior mesenteric artery (SMA) was performed with
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1 PV + SPV + SMV SMA (first) + PT (next) 6 Urokinase (3,200,000 IU) 5 Urokinase (2,800,000 IU) Urokinase (6,000,000 IU) 11
2 PV + SMV + IVC SMA + PT 3 Urokinase (600,000 IU) 7 Urokinase (2,600,000 IU) Urokinase (3,200,000 IU) 7
3 SMV PT + SMA 6 urokinase (1,700,000 IU) 6 Urokinase (1,200,000 IU) Urokinase (2,900,000 IU) 6
4 PV + SPV + SMV + IVC SMA 5 Alteplase (60 mg) +
urokinase (1,200,000 IU)
- - Alteplase (60 mg) +
urokinase (1,200,000 IU)
5
5 PV + SMV + IVC TI + SMA 3 Alteplase (10 mg) +
urokinase (600,000 IU)
6 Alteplase (110 mg) +
urokinase (400,000 IU)
Alteplase (120 mg) +
urokinase (1,000,000 IU)
6
6 PV + SPV + SMV PT + SMA 5 Alteplase (30 mg) 5 Alteplase (50 mg) Alteplase (80 mg) 5














a 5-Fr multiple side-hole catheter (Cordis, Miami, USA)
in order to perform the indirect PV-SMV thrombolytic
treatment.
Transcatheter anticoagulant and thrombolytic therapy
Following the mechanical aspiration procedure, a bolus of
5 mg of rt-PA (alteplase; Boehringer Ingelheim GmbH,
Germany) was injected via the catheter followed by con-
tinuous infusion of 0.625–0.833 mg/h for 24–48 h at the
ICU (laboratory analysis and thromboelastogram were per-
formed at 24-h intervals throughout the rt-PA infusion
period). Then, rt-PA was replaced with urokinase
(Nanjing Nanda Pharmaceutical Co. Ltd. Nanjing,
China) at 400,000–600,000 IU/day for 4–6 days.
After completion of the thrombolytic therapy, the in-
dwelling catheter was used to give low molecular heparin
infusions at a rate of 417 IU/h; in order to maintain the ac-
tivated partial thromboplastin time (APTT) at values two
times the control value throughout the hospitalization.
Termination of thrombolysis and timing of laparotomy
During transcatheter thrombolytic therapy, PV and SMV
patency of patients were assessed every 24 h by ultrason-
ography. The angiogram was repeated via the infusion
catheter at 24, 48 and 72 h and one week following the
procedure. Contrast-enhanced CT scan was performed
upon completion of thrombolytic therapy or in patients
with signs of peritonism or bloody ascites.
Termination of thrombolysis was based on clinical and
radiographic findings. Particularly, when CT demonstrated
intestinal perforation, transmural bowel necrosis, and ab-
dominal paracentesis revealed bloody ascites. Patients with
these findings were treated by laparotomy as soon as pos-
sible. Some abnormal serum markers and intra-abdominal
pressure are shown in Table 2. During surgery, resection of
the gangrenous bowel with double barrel enterostomy was
performed. In the presence of intra-abdominal hyperten-
sion, the abdomen was left open. Abdominal closure was
performed once intra-abdominal pressure returned to nor-
mal range. Definite intestinal anastomosis was performed
after patients completely recovered from the acute phase
and were on a full oral diet (Table 3).
Follow-up
After recovery from transcatheter thrombolysis and dam-
age control surgery, patients were discharged on oral antic-
oagulation, which was adjusted to maintain prothrombin
time at 4–6 s higher than normal values for six months.
Contrast enhanced CT and ultrasonography of the por-
tal vein and SMV was conducted at discharge, followed by
repeat imaging every three months for the first year, and
every 6–12 months thereafter. Records of hospitalization
and clinic visits were reviewed from the time of discharge
until October 31, 2014.
Results
Patient demographics
Among these six patients, three were male and three were
female; and mean age of patients was 41 ± 14.38 years
(range, 20–59 years). Initial symptom of all patients was ab-
dominal pain, which was accompanied by the following
symptoms: abdominal distension (n = 5), nausea and vomit-
ing (n = 3), and hematemesis (n = 1). All six patients experi-
enced abdominal pain for less than two weeks (range, 5–14
days; mean, 9 ± 3.82 days). Related past medical history and
risk factors in our study are presented in Table 4.
ASMVT was diagnosed and evaluated by MSCT. All
patients underwent MSCT to detect SMV thrombosis
and bowel affected by ischemia (Figs. 1 and 2). Based on
clinical symptoms and CT findings, all patients under-
went thrombolytic therapy.
Thrombolytic therapy
Six patients were successfully treated with direct PV-SMV
thrombolysis and SMA thrombolysis (Figs. 1 and 2). Patient
No. 1 first received trans-SMA thrombolysis for six days,
and was treated with trans-SMV thrombolysis for 5 days.
Patient No. 4 only received SMA thrombolysis therapy for
5 days due to failure of direct PV-SMV catheterization.
Catheter-directed mechanical thrombectomy was per-
formed in three patients. Continuous thrombolysis via the
Table 2 Biochemical and hematological parameters of patients 24 h before exploratory laparotomy
No. of patients WBC (109/L) CRP (mg/L) D-dimer (mg/L) PCT (μg/L) Albumin (g/L) Lactate (mmol/L) LDH (U/L) LAP (U/L) IAP (cmH2O)
1 19 144 2.55 21.16 34.3 19.6 230 61 8
2 19.4 140.6 2.25 23.94 29.4 17.6 171 65 10
3 39.1 190 1.45 12.26 30.5 21.3 339 76 13
4 19.9 189 18.79 55.27 27.9 16.4 437 78 5
5 32.9 150 8.55 5.13 30.0 25.8 980 65 9
6 22.8 151.3 3.54 14.45 24.5 15 959 103.9 6
Reference range: white blood cell (WBC): 3.5–9.5 × 109/L, Creactive protein (CRP): 0–8 mg/L, D-dimer: 0–0.55 mg/L, procalcitonin (PCT): 0–0.5 μg/L, Albumin: 40.0–55.0 g/L,
Lactate: 0.5–1.6 mmol/L, lactate dehydrogenase (LDH): 109–245 U/L, leukocyte alkaline phosphatase (LAP): 30–120 U/L, intra-abdominal pressure (IAP): 0 kPa. 1
kPa = 10.2 cmH2O
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Initial findings and treatment Range of small
bowel resection












1 7 Bowel resection, double barrel
enterostomy and open abdomena
200 cm 3 27 12 No further intestinal necrosis. 37 No recurrence
double-cavity stoma
reversion
2 7 Bowel resection, double barrel
enterostomy and open abdomena
200 cm 3 47 12 No further intestinal necrosis. 32 No recurrence
double-cavity stoma
reversion
3 7 Bowel resection, double barrel
enterostomy and open abdomena
150 cm 7 29 12 No further intestinal necrosis. 25 No recurrence
double-cavity stoma
reversion
4 18 Bowel resection and double
barrel enterostomy
150 cm - 70 12 No further intestinal necrosis. 20 No recurrence
double-cavity stoma
reversion
5 8 Bowel resection, double barrel
enterostomy and open abdomena
250 cm 3 38 12 No further intestinal necrosis. 16 No recurrence
double-cavity stoma
reversion
6 6 Bowel resection and double
barrel enterostomy
80 cm - 40 13 No further intestinal necrosis. 11 No recurrence
double-cavity stoma
reversion














Table 4 Summary of clinical data
No. of patients Age (years)/ gender Initial symptoms and signs Etiologies Past medical history and
risk factors




1 46/M Abdominal pain, distention Portal hypertension Portal hypertension Continued pain, despite
anticoagulation
5 7







3 29/F Abdominal pain, distention Post partum, IgA
nephropathyand
hypercoagulable state










Oral contraceptive agent Worsening pain, despite
anticoagulation
8 9


































infusion catheter in the SMV was provided for 5–7 days
(average, 5.8 ± 0.84 days). The mean doses of thrombolytics
via SMV access were: alteplase, 80 ± 42.43 mg; urokinase,
1.75 ± 1.15,000 000 IU. SMA trans-catheter thrombolysis
lasted for 3–6 days (average, 4.67 ± 1.37 days). The mean
doses of thrombolytics via SMA access were: alteplase,
33.3 ± 25.12 mg; urokinase, 1.46 ± 1.08,000 000 IU. The
total doses of thrombolytics were: alteplase, 86.67 ±
30.55 mg; urokinase, 2.86 ± 2.01,000 000 IU. After com-
pletion of the infusion of thrombolytic drugs, venography
via the infusion catheter was performed to observe the
thrombolytic effect on SMV thrombosis. MSCT images
were obtained again before surgery, which revealed the re-
canalization of SMV and the necrotic intestine.
Damage control surgery
All six patients underwent exploratory laparotomy
due to worsening of symptoms with the development
of hemodynamic instability. During the procedure,
hemorrhagic ascites were found along with intestinal
Fig. 1 Patient No. 5: a MSCT demonstrates the massive thrombosis of the portal vein (PV) and superior mesenteric vein (SMV) (black arrow), diffuse
circumferential bowel wall thickening with “halo sign” (white arrows), and the small amount of ascites (star). b Venography of the superior mesenteric
and portal veins demonstrates filling defects in the lumen of PV and SMV via the percutaneous transhepatic route (black arrow). c MSCT demonstrates
partial recanalization of PV and SMV (black arrow) and collateral vessels 12 months after surgery
Fig. 2 Patient No. 3: d MSCT demonstrates the massive thrombosis of the portal vein (PV) and superior mesenteric vein (SMV) (black arrow), diffuse
circumferential bowel wall thickening with “halo sign” (white arrows), and the small amount of ascites (star). e Venography of the superior mesenteric
and portal veins demonstrates filling defects in the lumen of PV and SMV via the transjugular intrahepatic route (black arrow). f MSCT demonstrates
partial recanalization of PV and SMV (black arrow) at discharge
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gangrene and mesenteric edema. SMA pulsations
were palpable, but mesenteric veins of the bowel were
dilated and filled with red thrombi. Necrotic bowel
resection and double barrel enterostomy were per-
formed in all patients, in which four patients also
underwent open abdomen due to sustained intra-
abdominal hypertension. Mean length of the resected
bowel was 171.67 ± 58.45 cm (range, 80–250 cm;
Fig. 3)
Definitive surgery for restoring intestinal continuity
was performed 6–12 months later.
Complications
During thrombolytic infusion via the indwelling catheter,
a small hematoma was observed in three patients at both
the arterial or venous puncture site; which were treated
conservatively without stopping thrombolytic therapy.
Sepsis occurred in one patient, while intestinal perforation
occurred in another patient before open exploration.
Follow-up
None of the patients required long-term parenteral nu-
trition. In addition, there was no mortality or thrombosis
recurrence until the last follow up. Mean duration of
hospitalization was 41.83 ± 15.63 days (range, 27–70
days), and mean duration of follow-up after discharge
was 23.5 ± 9.81 months (range, 11–37 months).
Discussions
ASMVT is a rare but potentially catastrophic clinical
complication that may lead to ischemia and/or infarction
of the intestine [1, 4, 5]. The mortality rate of acute mes-
enteric venous thrombosis is usually up to 50 % [9]. The
exact pathophysiology of acute SMV thrombosis remains
unclear. However, it has been associated with some risk
factors for thrombophilia such as myeloproliferative dis-
ease [12], coagulation factor deficiency, factor V Leiden
[13] and prothrombin gene mutation [14], portal hyper-
tension, post-splenectomy, malignancy, intra-abdominal
infection or inflammation [15], pregnancy, oral contra-
ceptive use, and so on.
Transcatheter thrombolysis is used to treat patients with
ASMVT and bowel ischemia to achieve early recognition
and mesenteric recanalization, and subsequently salvage
the adjacent bowel with reversible ischemia. Operative
intervention is reserved for patients with severe and dif-
fuse peritonitis, and transmural bowel infarction [16].
Damage control surgery is performed to remove the gan-
grenous bowel with minimum surgical stress, in order to
Fig. 3 Patient No. 5: Venous thromboembolus (g) aspirated from the superior mesenteric vein via the catheter. Damage control surgery after
thrombolysis: obvious transmural necrosis of the small intestine (h) temporary abdominal closure, and double stoma (i). Abdominal wound (k) at
discharge after damage control surgery is shown
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accelerate recovery from acute illness before performing
definitive surgery [17, 18].
In the absence of clear indications for surgery, sys-
temic anticoagulation therapy should be started as soon
as possible [6, 8]. Interventional catheter thrombolysis
may be more effective than systemic anticoagulation. For
acute thrombosis, local thrombolytic therapy via a catheter
introduced into the superior mesenteric vein or artery has
all been shown to have gratifying results [19–23]. The in-
direct and continuous infusion of fibrinolytic therapy
through the SMA is effective, because it enables the
thrombolytic agent to disperse from the capillaries and
small venules, tertiary and secondary arcades before reach-
ing the larger veins [22, 23]. Transarterial infusion can re-
duce the side effects of drugs such as bleeding, and avoid
intraperitoneal and hepatic subcapsular bleedings that may
result from the association of liver puncture and the use of
fibrinolytic agents and heparin [24]. Direct access to the
portal system targets SMV thrombosis by a transjugular or
transhepatic route, leading to rapid thrombus removal and
venous flow re-establishment, and an improvement in
symptoms [20–22]. Compared to the indirect method, dir-
ect thrombolysis is more efficient, less time-consuming,
and provides the opportunity to perform mechanical aspir-
ation and balloon angioplasty with possible stent place-
ment for elastic recoil or persistent stenosis.
We conducted arteriovenous combined thrombolysis
for these patients to reduce the need for greater lytic
agent doses and longer durations of infusion therapy
[22, 23]. There is no consensus on the best fibrinolytic
agent to be used and its correct dosage [25]. In our
study, alteplase was first used with a significantly smaller
initial bolus (5 mg), and was maintained for 24–48 h at
the recommended safe 0.625–0.833 mg/h infusion rate.
It has been reported that t-PA has demonstrated a
higher thrombolytic rate, less plasminogen activation,
less α2-antiplasmin consumption and less fibrinogen
breakdown when compared to urokinase [25]. Conse-
quently, when the effect of urokinase was not obvious,
we switched and used alteplase (tissue-type plasminogen
activator), which can selectively dissolve blood clots.
However, we cautiously reduced the dose of t-PA when
the risk of bleeding was taken into account.
Contrary to previous thinking, surgical exploration is
not necessary in all patients with mesenteric venous
thrombosis. Premature laparotomy would lead to exten-
sive resection of the small intestine, increase post-
operative mortality, and affect the clinical outcome of
patients [10, 16].
From our own perspective (Fig. 4), the first step is to
evaluate the extent and severity of intestinal ischemia.
Unfortunately, there are no precise markers that can
identify patients who are at risk for bowel infarction [2].
CT and laparoscopy may play a role in the diagnosis of
transmural bowel infarction [7, 26]. Prolonged stasis of
venous flow can cause arterial spasm, aggravating intes-
tinal ischemia. Therefore, in patients with suspected
acute mesenteric ischemia, revascularization is preferen-
tially started prior to bowel surgery [16]; and anticoagu-
lation treatment should be started immediately [6].
Compared to arterial thrombosis, intestinal ischemia
caused by venous thrombosis has a slow development. It
Fig. 4 Proposed treatment strategy for acute mesenteric venous thrombosis is shown
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is noteworthy to mention that ischemic lesions occur
first in the mucosa, which may be extensive. Thrombo-
lytic therapy should be performed angiographically in an
attempt to avoid further infarction. Previous studies have
emphasized that longer durations of ischemia prior to
treatment are associated with poorer prognosis [27].
Early catheter thrombolysis can restore blood flow to is-
chemic bowel and achieve maximum retention of the
remaining intestine.
If bowel ischemia fails to reverse, intestinal gangrene
occurs; leading to sepsis. In such cases, damage control
surgery like bowel resection with double barrel enteros-
tomy is preferred over complex definitive procedures in
order to reduce second hit phenomenon in such critic-
ally ill patients [11, 17].
Double barrel enterostomy allows the observation of
the color and vitality of the stoma, which provides an in-
direct assessment of the intestinal blood supply and
avoids a second-look operation. Sometimes, temporary
abdominal closure with prolene Mesh (Ethicon, LLC,
USA) may be applied when there is severe bowel edema
with risk of intra-abdominal hypertension or abdominal
compartment syndrome [18].
This study has some limitations. Firstly, this is a retro-
spective study with a small sample size; hence, further
comparative prospective trials are required to validate the
findings of this study. Secondly, transcatheter thrombolysis
can cause delay in damage control surgery, which can lead
to bowel perforation, sepsis and deterioration of the pa-
tient’s clinical condition; as seen in one of our patients.
Hence, continuous close monitoring is required dur-
ing thrombolytic therapy in order to prevent undue
delay in surgery.
Conclusions
For critically ill patients with acute mesenteric venous
thrombosis, transcatheter thrombectomy and thromb-
olysis may be useful to restore blood flow, improve in-
testinal ischemia, and avoid extensive bowel necrosis. By
using the damage control strategy, necrotic bowel is
resected, metabolic disturbance is corrected, and finally,
definitive surgery is completed. The stepwise surgical ap-
proach for ASMVT needs further researches to provide
more evidence-based data, to improve survival and prog-
nosis of patients [11].
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LK, MJX, DWW and WXJ carried out the surgery, and drafted the manuscript.
LK, MJX, YSF, participated in the design of the study and performed the statistical
analysis. LBC, DWW and LJS conceived of the study, and participated in its design
and coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
Author details
1Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R.
China. 2Research Institute of General Surgery, Jinling Hospital, 305 East
Zhongshan Road, 210002 Nanjing, Jiangsu, China.
Received: 28 September 2015 Accepted: 21 October 2015
References
1. Acosta S, Ögren M, Sternby N-H, Bergqvist D, Björck M. Mesenteric venous
thrombosis with transmural intestinal infarction: a population-based study.
J Vasc Surg. 2005;41:59–63.
2. Glenister KM, Corke CF. Infarcted intestine: a diagnostic void. ANZ J Surg.
2004;74:260–5.
3. Harnik IG, Brandt LJ. Mesenteric venous thrombosis. Vasc Med. 2010;15:407–18.
4. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med.
2001;345:1683–8.
5. Singal AK, Kamath PS, Tefferi A. Mesenteric venous thrombosis. In: Mayo Clinic
Proceedings. Elsevier; 2013. p. 285–94.
6. Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N,
Armellino MF, et al. Prognostic factors in noncirrhotic patients with
splanchnic vein thromboses. Am J Gastroenterol. 2007;102:2464–70.
7. Duran R, Denys AL, Letovanec I, Meuli RA, Schmidt S. Multidetector CT features
of mesenteric vein thrombosis. Radiographics. 2012;32:1503–22.
8. Joh J-H, Kim D-I. Mesenteric and portal vein thrombosis: treated with early
initiation of anticoagulation. Eur J Vasc Endovasc Surg. 2005;29:204–8.
9. Abdu RA, Zakhour B, Dallis D. Mesenteric venous thrombosis–1911 to 1984.
Surgery. 1987;101:383–8.
10. Kim H-K, Chun JM, Huh S. Anticoagulation and delayed bowel resection in
the management of mesenteric venous thrombosis. World J Gastroenterol.
2013;19:5025.
11. Yang S, Wu X, Li J. Transcatheter thrombolysis centered stepwise management
strategy for acute superior mesenteric venous thrombosis. Int J Surg. 2014;12:442–51.
12. Michiels J, Commandeur S, Hoogenboom G, Wegman J, Scholten L, Van
Rijssel R, et al. JAK2V617F positive early stage myeloproliferative disease
(essential thrombocythemia) as the cause of portal vein thrombosis in two
middle-aged women: therapeutic implications in view of the literature. Ann
Hematol. 2007;86:793–800.
13. Famularo G, Minisola G, Nicotra GC, Simone C. Mesenteric and portal vein
thrombosis associated with hyperhomocysteinemia and heterozygosity for
factor V Leiden mutation. World J Gastroenterol. 2005;11:7700.
14. Vayá A, Plumé G, Bonet E, Carrasco P, Morales-Suárez-Varela MM.
Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T
mutation in splanchnic vein thrombosis. Eur J Haematol. 2011;86:167–72.
15. Hatoum OA, Spinelli KS, Abu-Hajir M, Attila T, Franco J, Otterson MF, et al.
Mesenteric venous thrombosis in inflammatory bowel disease. J Clin
Gastroenterol. 2005;39:27–31.
16. Acosta S. Surgical management of peritonitis secondary to acute superior
mesenteric artery occlusion. World J Gastroenterol. 2014;20:9936.
17. Jansen J, Loudon M. Damage control surgery in a non-trauma setting.
Br J Surg. 2007;94:789–90.
18. Waibel BH, Rotondo MM. Damage control surgery: it’s evolution over the
last 20 years. Rev Col Bras Cir. 2012;39:314–21.
19. da Motta Leal Filho JM, Santos ACB, Carnevale FC, de Oliveira Sousa W, Grillo
LSP, Cerri GG. Infusion of recombinant human tissue plasminogen activator
through the superior mesenteric artery in the treatment of acute mesenteric
venous thrombosis. Ann Vasc Surg. 2011;25:e1-840. e4.
20. Ferro C, Rossi UG, Bovio G, Dahamane MH, Centanaro M. Transjugular
intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and
direct thrombolysis in the treatment of acute portal and superior mesenteric
vein thrombosis. Cardiovasc Intervent Radiol. 2007;30:1070–4.
21. Kim HS, Patra A, Khan J, Arepally A, Streiff MB. Transhepatic catheter-
directed thrombectomy and thrombolysis of acute superior mesenteric
venous thrombosis. J Vasc Interv Radiol. 2005;16:1685–91.
22. Liu F-Y, Wang M-Q, Fan Q-S, Duan F, Wang Z-J, Song P. Interventional
treatment for symptomatic acute-subacute portal and superior mesenteric
vein thrombosis. World J Gastroenterol. 2009;15:5028.
23. Yang S, Liu B, Ding W, He C, Wu X, Li J. Acute Superior Mesenteric Venous
Thrombosis: Transcatheter Thrombolysis and Aspiration Thrombectomy
Therapy by Combined Route of Superior Mesenteric Vein and Artery in
Eight Patients. Cardiovasc Intervent Radiol. 2015;38:88–99.
Liu et al. World Journal of Emergency Surgery  (2015) 10:50 Page 10 of 11
24. Henao E, Bohannon WT, Silva M. Treatment of portal venous thrombosis
with selective superior mesenteric artery infusion of recombinant tissue
plasminogen activator. J Vasc Surg. 2003;38:1411–5.
25. Kozuch P, Brandt L. Review article: diagnosis and management of mesenteric
ischaemia with an emphasis on pharmacotherapy. Aliment Pharmacol Ther.
2005;21:201–15.
26. Cho YP, Jung SM, Han MS, Jang HJ, Kim JS, Kim YH, et al. Role of diagnostic
laparoscopy in managing acute mesenteric venous thrombosis. Surg Laparosc
Endosc Percutan Tech. 2003;13:215–7.
27. Park WM, Gloviczki P, Cherry KJ, Hallett JW, Bower TC, Panneton JM, et al.
Contemporary management of acute mesenteric ischemia: factors associated
with survival. J Vasc Surg. 2002;35:445–52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. World Journal of Emergency Surgery  (2015) 10:50 Page 11 of 11
